Preventing fractures in older patients on ADT

Men with prostate cancer who are 70 years of age or older, and who are starting adjuvant androgen deprivation therapy (ADT) for locally advanced or high-risk localized prostate cancer, should receive a bone mineral density (BMD) test followed by selective bisphosphonate therapy for those with osteoporosis, according to an article in today’s issue of Annals of Internal Medicine. … READ MORE …

Prostate cancer news reports: Wednesday, May 13, 2009

This morning’s reports deal with:

  • New Japanese guidelines on prostate cancer screening
  • PCA3 — “from bench to bedside”
  • Impact of hormonal therapy on bone mineral density and risk for fractures
  • The initial results of the RENEW trial … READ MORE …

The news report: Friday, April 10, 2009

Today’s news reports deal with:

  • A comparative, single institution study of RALP vs RRP
  • Bone mineral density and osteoporosis in men treated with intermittent hormone therapy
  • Transdermal testosterone therapy in men with castration-resistant prostate cancer

In a separate report we have discussed the development of a pre-biopsy risk assessment nomogram that incorporates results from PCA3 testing. … READ MORE …

The Tuesday news report: January 20, 2009

Today’s inauguration day (here in the USA) news reports address:

  • Obesity and prostate cancer screening PSA levels
  • The possible association of bone mineral density with prostate cancer risk in older men
  • Soy, genistein, and the inhibition of prostaglandins
  • Pathologic prostate specimen weight and perioperative outcomes in LRP … READ MORE …